Nk-1 receptor antagonists for the treatment of delayed emesis

Details Nk-1 receptor antagonists for the treatment of delayed emesis Nk-1 receptor antagonists for the treatment of delayed emesis

A - Human Necessities

61

K

A61K 31/435 (2006.01) A61K 31/439 (2006.01) A61K 31/451 (2006.01) A61K 33/24 (2006.01)

Patent

CA 2233377

Disclosed is a pharmaceutical composition comprising an NK-1 receptor antagonist (e.g., substance P receptor antagonist) for treatment delayed emesis. More specifically, the composition comprises a therapeutically effective amount of: (2S,3S)-3-(2-methoxy-5-trifluoromethoxybenzyl)amino-2- phenylpiperidine; (2S,3S)-N-(5-tert-butyl-2-methoxyphenyl)- methyl-2-diphenylmethyl-1-azabicyclo[2.2.2]octan-3-amine; or (2S,3S)-N-(5-isopropyl-2-methoxyphenyl)methyl-2-diphenyl- methyl-1-azabicyclo-[2.2.2]octan-3-amine; or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier or diluent.

Divulgation d'une composition pharmaceutique comprenant un antagoniste du récepteur des NK-1 (p. ex., antagoniste du récepteur de la substance P) pour le traitement des vomissements à retardement. Plus précisément, la composition comporte une quantité efficace sur le plan thérapeutique de : (2S,3S)-3-(2-méthoxy-5-trifluorométhoxybenzyl)amino-2-phénylpipéridine; (2S,3S)-N-(5-tert-butyl-2-méthoxyphényl)-méthyl-2-diphénylméthyl-1-azabicyclo¢2.2.2!octan-3-amine; ou (2S,3S)-N-(5-isopropyl-2-méthoxyphényl)méthyl-2-diphényl-méthyl-1-azabicyclo¢2.2.2!octan-3-amine; ou un de ses sels acceptable sur le plan pharmaceutique conjugué à un excipient ou à un diluant acceptable sur le plan pharmaceutique.

Affiliated with

Also associated with

Rating

Nk-1 receptor antagonists for the treatment of delayed emesis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Nk-1 receptor antagonists for the treatment of delayed emesis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nk-1 receptor antagonists for the treatment of delayed emesis will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1640343